Indivior Pharmaceuticals, Inc. Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2026-06-30 was -169.05%, a change of -127.35% year-over-year.
- Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2026-03-31 was -171.92%, a 7148.63% decline year-over-year.
- Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2025-12-31 was -209.00%, a change of -206.94% year-over-year.
- Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2025-09-30 was -61.24%.
- Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2025 was -210.00%, a change of -207.94% from fiscal 2024.
- Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2024 was -2.06%, a 103.10% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2023 was 66.67%, a 77.27% decline from fiscal 2022.
- Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2022 was 293.33%.
- Available history
- 2022-12-31 to 2026-06-30
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |